TAKEDA PHARMACEUTICAL CO LTD - 17 Sep 2025 Form 4 Insider Report for HilleVax, Inc. (HLVX)

Reporting relationship: 10%+ Owner
Issuer ticker: HLVX
Reported as of: 17 Sep 2025
Net transaction value: -$13,111,800
SEC form: 4
Accepted by SEC: 19 Sep 2025, 07:23:13 UTC
Prior SEC filing: 25 Jan 2024
Next SEC filing: 09 Dec 2025
Source filing: View source filing
Reporting owner signature: /s/ Paul Sundberg, Authorized Signatory, Takeda Pharmaceutical Company Limited

Key filing fact

TAKEDA PHARMACEUTICAL CO LTD filed Form 4 for HilleVax, Inc. (HLVX) on 19 Sep 2025.

Key facts

This page summarizes TAKEDA PHARMACEUTICAL CO LTD's Form 4 filing for HilleVax, Inc. (HLVX).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 19 Sep 2025, 07:23.

Change

Previous filing in this sequence was filed on 25 Jan 2024.
Current net transaction value: -$13,111,800.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (2)

CIK 0001395064 Primary reporting owner

TAKEDA PHARMACEUTICAL CO LTD

Relationship: 10%+ Owner
Address: 1-1, NIHONBASHI-HONCHO 2-CHOME, CHUO-KU, TOKYO, JAPAN
Signature: /s/ Paul Sundberg, Authorized Signatory, Takeda Pharmaceutical Company Limited
Signature date: 19 Sep 2025

CIK 0001905616

Takeda Vaccines, Inc.

Relationship: 10%+ Owner
Address: 75 SIDNEY STREET, CAMBRIDGE
Signature: /s/ Max Heuer, Authorized signatory, Takeda Vaccines, Inc.
Signature date: 19 Sep 2025

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

HLVX transaction

Common Stock

Disposition pursuant to a tender of shares in a change of control transaction

Transaction value: $13,111,800
Shares: -6,724,000
Change %: -100%
Price: $1.95
Shares after: 0
Date: 17 Sep 2025
Ownership: See Explanation of Responses
Footnotes: F1, F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Section 16 status

TAKEDA PHARMACEUTICAL CO LTD is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may still apply in specific circumstances.

Explanation of responses 2 footnotes

Footnote F1

These shares were sold pursuant to the cash tender offer (the "Tender Offer") by XOMA Royalty Corporation, a Nevada corporation ("Parent") and XRA 4 Corp., a Delaware corporation and a wholly owned subsidiary of Parent, to purchase all of the outstanding shares of common stock of the Issuer at an offer price of (i) $1.95 per share of common stock and (ii) one non-transferable contractual contingent value right. The Tender Offer expired as scheduled at one minute after 11:59 p.m., Eastern Time, on September 15, 2025 (the "Expiration Time") and closing of the Tender Offer was announced on September 17, 2025. As all conditions to the Tender Offer were satisfied or waived, on September 17, 2025, Parent irrevocably accepted for payment all shares validly tendered into and not validly withdrawn from the Tender Offer and paid for all such shares in accordance with the Tender Offer.

Footnote F2

Takeda Pharmaceutical Company Limited has beneficial ownership of the reported securities, all of which are held directly by Takeda Vaccines, Inc., an indirect wholly-owned subsidiary of Takeda Pharmaceutical Company Limited. Takeda Vaccines, Inc. is owned directly by Takeda Pharmaceuticals U.S.A., Inc., which is owned directly by both Takeda Pharmaceutical Company Limited (72.70%) and Takeda Pharmaceuticals International AG (27.30%). Takeda Pharmaceuticals International AG is a wholly-owned direct subsidiary of Takeda Pharmaceutical Company Limited.

SEC remarks

Intentional misstatements or omissions of facts constitute Federal Criminal Violations.